Specialty Pharmacy Network and BeiGene

Selected news for the healthcare topic - Specialty Pharmacy Network, and the company - BeiGene. We have a small number of shared news items for this connection to-date.

Please provide a valid email address.
Specialty Pharmacy Network Shares Healthcare News With (link):
Healthcare Topics
Companies
Health Systems
People

Selected Headlines

Date Headline (link) Source Relevant Snippet
11/21/2019 BRUKINSA™ (zanubrutinib) Approved for the Treatment of Mantle Cell Lymphoma, Available from Onco360 | Malvern Daily Record Onco360 ® , the nation’s largest independent Oncology Pharmacy, has been selected by BeiGene to be a specialty pharmacy network partner for BRUKINSA ™ (zanubrutinib), a new oral treatment for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. “The approval of BRUKINSA as a second-line therapy option for patients with relapsed and refractory MCL is an important advancement in fighting this devastating disease,” said Paul ...
11/21/2019 BRUKINSA™ (zanubrutinib) Approved for the Treatment of Mantle Cell Lymphoma, Available from Onco360 | BioSpace BRUKINSA™ (zanubrutinib) Approved for the Treatment of Mantle Cell Lymphoma, Available from Onco360 Published: Nov 21, 2019 LOUISVILLE, Ky.--( BUSINESS WIRE )-- Onco360 ® , the nation’s largest independent Oncology Pharmacy, has been selected by BeiGene to be a specialty pharmacy network partner for BRUKINSA ™ (zanubrutinib), a new oral treatment for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. “The approval of BRUKINSA as a second ...
11/21/2019 BRUKINSA™ (zanubrutinib) Approved for the Treatment of Mantle Cell Lymphoma, Available from Onco360 Business Wire LOUISVILLE, Ky.--(BUSINESS WIRE)--Nov 21, 2019-- Onco360 ®, the nation’s largest independent Oncology Pharmacy, has been selected by BeiGene to be a specialty pharmacy network partner for BRUKINSA ™ (zanubrutinib), a new oral treatment for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. “The approval of BRUKINSA as a second-line therapy option for patients with relapsed and refractory MCL is an important advancement ...
11/21/2019 BRUKINSA™ (zanubrutinib) Approved for the Treatment of Mantle Cell Lymphoma, Available from Onco360 LOUISVILLE, Ky.–(BUSINESS WIRE)–Onco360 ® , the nation’s largest independent Oncology Pharmacy, has been selected by BeiGene to be a specialty pharmacy network partner for BRUKINSA ™ (zanubrutinib), a new oral treatment for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. “The approval of BRUKINSA as a second-line therapy option for patients with relapsed and refractory MCL is an important advancement in fighting this ...